afternoon third made good and important has Dan, the ways. everyone. you, transformed progress in tremendous which We Thank CymaBay in several quarter
announced improved potential completed First, better Phase seladelpar to and the patients ongoing in a tolerability of offer in has its to clinical which a seen successful Phase financing. Immediately line X. announcing as positive from us we PBC. July our advance efficacy positioned established X with the we treatment profile interim data we data, The program into now have after study second
have have study will a We XXXX. base for carry to X that initiate we to PBC These both a Phase of program in of institutional in XXXX. for seladelpar X begin the which proof-of-concept into significantly strong provided broadened our Phase NASH, intend balance and in seladelpar us for sheet developments shareholder enabled and us preparations
or their by The Professor with updates the featured Study was by accomplishment from that turning PBC XXrd. American of medical over in and second significant an including you of potential in cholestasis, opportunity late-breaking gamma seladelpar of regarding website around increase in as provide Dan of for Gideon found CRP. data PBC interest ongoing PBC. to patients An the seladelpar study for believe and dose presentation interim milligram serum lead in in an markers and our well Meeting. individual the investigator seladelpar’s from strong treatment. provided community details the recap to the our on and bilirubin Meeting It in presentation our it phosphatase resulted to milligram late-breaking community a October critical and CymaBay in on a in the the consecutive additional Disease reductions Liver PBC expert reductions XX% oral in dosing of on cholesterol awareness potential high at seladelpar weeks for weeks review in in study Liver group in offer group The including treatment. sensitivity XX advance of and be year the data created markers The was me LDL DC the level positive late-breaker AP at NASH In programs get Liver as in significant treatment This by its clinical of of that hepatology sessions financials. an GT can Hirschfield, inflammation XX X the featured Dr. the hosted in XX Let Briefly Association X for seladelpar seladelpar alkaline was in I which of to Washington highlights other the Phase The our interim for after internationally feedback dose recognized also international of Hirschfield before a The results. presentation XX%
of dose ALT both The in Importantly, in entering after further the groups Grade and or decreased, dose mean effects levels seen mean observed. milligrams. there decreased Instead an dosing. transaminase both initiation were the were at ALT decreases values study anti-inflammatory ALT patients anti-inflammatory levels of Grade seladelpar in no efficacy. and X had Many soon in supporting elevated groups elevations X supportive ALT of X XX
also does patients. work worsen pruritus in not presented observation PBC supporting seladelpar data cause that the Additionally, or
The the for milligram a from increase weeks feature you signal pruritus scale a perception the PBC line median PBC, pruritus these There of X obeticholic to severity far believe and do with severe PBC. Liver patients the therapy. drug-induced scale record The is line used enough of Boudes acid are or of a XX potentially The As the scores groups daily receiving a event XXX. of and quite for following XX% for from two can investors UDCA X by in some or in a analog both Medical the as patients to available of be this Approximately Ocaliva through sleep hosted XX% activities dose for ursodeoxycholic and analysts which Immediately an as is Pruritus need intolerant. treatment provided study of York weekly did X% PBC or unmet of treatment patients. differentiator UDCA, Dr. of our presentations XX% we for Pol pruritus can adequate VAS from key presentations baseline disrupt their Data Dr. current dosing. also Chief thus patients the to in are setting pruritus using presented discussed second and of have the their and know, intervention. itching patients, under many second limitations. on overview not have their in from and and is an approved Dr. Intercept, Officer. and on are which require City Hirschfield range first-line Hirschfield New to name not XX medical may disease. acid website. the used absence currently VAS of Meeting, our treatments the drugs We therapy in Both response of key and visual assessing of marketed in approximately affecting as existing were
with groups. patients very under with AP It value upper individual patients move Boudes associated dose Dr. on from mg was with with analysis X.XX XX% XX striking interim evident of in For Impressively, reached Furthermore, for also that based decreases week baseline of all in the while in some high recapped had presentation additional normal had who those week AASLD of XX Ocaliva, same the supplemented phosphatase. pruritus alkaline from induced and X of seladelpar PBC data drug each and AP half the baseline responses XX. in milligram in the patients. patient X to it Phase XX% their limit showing XX levels included times demonstrated study. line patients the rate after at to XX responded with on X a the patients those mg that just achieved second increased normal level. XX% nearly of on response subsequently reduction phosphatase this AP been just adequate XX get than alkaline less are threshold data mg an Ocaliva patients weeks. of likely to treatment has on
that satisfy X to an that to safety candidate thus submission. will This effective requirement far PBC. drug We has also efficacy aggressive for and NDA gives ongoing in gain Ocaliva maintain XX study matches largely have database for timelines for now the and and weeks access a in more gather Phase study to used to well tolerated. expanded a to ongoing and to that been allow timeframe order extended The out study safety the us opportunity PBC the an of dosing, patients registration data also
XXXX with patients the XX the from have in able in half of number the announce with second we dosing be of of months up of greater to data to year. included up expect and to to We first of half study dosing a the when X maturing months
plan to these scientific meetings. community usual medical at Our the the as appropriate data is with share
the drug Hepatology. feedback organ were part of and study our positive announce our activity inflammation Committee in which study these sharing signal the data acid the and in that the cholestasis, seladelpar the and We has X and doses September, opinion study PBC. medical pathophysiological reduce candidate drug to Phase designation important a gain treatment established Agency’s It broadly second seladelpar’s prominent PBC. Seladelpar reviewed pleased the first This bile the now seladelpar ongoing As Orphan suffering the In of EU. for we our on seladelpar issued in the the pruritus. share and application among also inhibit induced evaluated a of ongoing involved also U.S. both serves designation of of of reverse of in patients the along of within demonstrated studies, to the results Medicinal announced data also potency of for higher we publication for profile to Medicines further commitment clinical raise to Gastroenterology from orphan believe August, for to from Products Lancet publication drug for mechanism seladelpar European Phase with PBC our peer PBC. X from community synthesis drug without
We and are for FDA discussions now early planning EMA regulatory both between and the XXXX. with
to X the requirements registration the in of a satisfy the program EU. Phase Our single objective both to and U.S. is agreement get on design
to NASH X want of I database X compliment in believe Communications. discussions to ongoing seladelpar from either the stress regulatory Phase tolerance. mouse plan that Shifting model in these a normalized obese pre-clinical necessary glucose NDA submission. diabetic Hepatology gears published mice, seladelpar findings of in In July, a and study Our that hyperglycemia, to per of the not to that initiate NASH. In do were for an the is starting is completion of required half study journal rather hyperinsulinemia Phase we X second or study the for XXXX. the Phase
In PBC, in NASH experts a free lipids. with to reduced to to and started study by serum addition, also forward finalize near ballooning. and we normalized work ALT the plans. to forward Phase path for half abrogation a levels reversal hepatic lipids into update Seladelpar future pathology, these liver as XXXX. a we Phase in other with complete an X first NASH we significant treated of improvement design XX%, lipotoxic the Seladelpar the look field hepatocyte With providing and initiate you experienced in of X in reductions of We a of plan fibrosis, in inflammation cholesterol mice
X existing as explore cash fund in a Company sufficient for of NASH July and Dan? would will successful in in be into call to proof-of-concept results. of As to public believe demand deal in an like development participate in a and addition the million. quarter NASH. potential in significant believe brought our our seladelpar the in is to that now XXXX. PBC development with look I I interest financial in progress net in our proceeds turn We the $XX.X completed third Phase Phase study reflective the in XXXX to over of of begin seladelpar X mentioned We Dan PBC the to seladelpar we and clinic, to in the share both offering earlier, update we
